Interim report
Page 1
Marksans Pharma Ltd. 11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: companysecretary@marksanspharma.com www.marksanspharma.com November 04, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relation Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block - G Dalal Street Bandra-Kurla Complex Mumbai – 400001 Bandra (East), Mumbai - 400051 Scrip Code: 524404 Symbol: MARKSANS Sub: Outcome of Board Meeting Dear Sir/Madam, Pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) and other regulations, if applicable, we enclose herewith the Unaudited Financial Results ( Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026 approved by the Board of Directors of the Company at its Me eting held today i.e. November 04 , 2026 along with Limited Review Reports thereon. Pursuant to Regulation 33 of the Listing Regulations as amended, we hereby declare that M/s. MSKA & Associates LLP, Chartered Accountants, the Statutory Auditors of the Company have submitted the Limited Review Reports for Unaudited Financial Results ( Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026 with an unmodified opinion. The aforesaid information is also available on the website of the Company at http://www.marksanspharma.com/quarterly-results.html The meeting commenced at 12:10 p.m. and concluded at 01:20 p.m. We request you to note the aforesaid in your records. Thanking you. Yours faithfully For Marksans Pharma Limited Harshavardhan Panigrahi Company Secretary Enclosed as above
Page 2
MSKA & Associates LLP o Flor 6, Rahesa Tianium (Formerly known as M S K A & Associates) \é@ftemcixlpress :ighnvay, GeGetaniali © olony, Ram Nagar, Goregaon Chartered Accountants by 400063, INDIA & Tel: +91 22 6974 0200 Independent Auditor’s Review Report on Standalone unaudited financial results of Marksans Pharma Limited for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. To The Board of Directors of Marksans Pharma Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results of Marksans Pharma Limited (hereinafter referred to as ‘the Company’) for the quarter ended 30 September 2026 and the year to-date results for the period from 01 April 2026 to 30 September 2026 (‘the Statement’) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘the Regulations’). 2. This Statement, which is the responsibility of the Company’s Management and has been approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued thereunder (‘Ind AS 34’) and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For M S K A & Associates LLP (Formerly known as M S K A & Associates) Chartered Accountants ICAl Firm Registration No.105047W/W101187 e Nitin Tiwari Partner Membership No.: 118894 UDIN:26 \b Ay AHLY Y K h by Place: Mumbai Date: 04 November 2026 Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India Tel: +91 22 6974 0200 | LLPIN: ACT-3789 Ahmedabad | Bengalury | Chandigarh | Chennai | Coimbatore | Goa | Gurugram | Hyderabad | Kochi | Kolkata | Pune www.mska.in
Page 3
€99 oze e ocz L 831 v9'9 eze e e 2 691 ) .83 1.2 J0 31eys Aunbs sad sBulse3| zk v6'690°01 finba ouio| Lt 9LESY oL'ESy oL'esy o1'esy oL'Esy oL'esy yoea | enjeA 30e)) (BdeD areys Aynb3 dnpled| 01 6CLL0%E EA9Ty 66055'F ZE 168 16768 zo8ss (8+2) awodu) snsuayaidwog ji0L| 6 oL (os'!) 0zs. [£250) 09 097 20U aasuBYBIdWOD JBUIO| 8 (os'e] 150 (221] 920 (g0 (6g70] 2A0QE U0 Xe | 16EL (02 59 (00't) av'e 6v'E sue|d ST PRULEP 13U B} JO SIUALIRINSERWDY| 5501 40 101 O} PAYISSLI98. 3G 10U (I U} Swa}| 2W0oU] IAISUIYRIAWOD JPUIO) B6500¢€ Z98LV L 6LGvS'L 50868 76069 Zr'ss8 (9:5) ¥ep souy woud| £ 5v°806 S0z 2609¢ 18917 12T [VETTS esusdxaxeL jeiol| 9 bS5 XD ¥00L L 0 €96 xey pauiajeg (0) oLt = {o+0) - (o010} - pouad Jailiea o) xe} yuain) (q)| (4% Erese 8605 50'802 06ELT 80°2EL xeljusin) (€) sosuadxa xeL EVSIEE 49058+ LL906'L E6VITL 8506 £4Z00°L (v-¢) xey a1008 Woud| S SOVESOL L0°€51'S £E061'S L815T 6618V PEBOLT sasuadx3 leioL( b LT STHLLL BvzzLL £EVYS zov6r 98269 sasusdxe IO © oczve vrooL 928l 918 ] 0506 ‘asuadve uogesiowe pue uogepa:dag| o zel 28 29 sie ore e siso0 soueutd| 3 ezt 09°€95 1889 95'82 sLue 95028 asusdxa syyaueq sakodws| G 8628 (v98) (651) (€212 (ez'81) ve'ol SPEIUPROIS pUE| s53.601d-U-j10m 'SpO0E pausiuy Jo SaOUBAU U] S36URD) 2908L veLey 60628 98602 9z 08L e 2PeI-UISROIS Jo asewoind| 8 Zvzo's L6 19216 ro'ser'L evovL 8L96Y'L pawnsuo sieudlew j01s00| Y sesusdx3| 60°05V'YL. YLIE00L YOL60°L 0E'9BLE 15°988°C 0Ie (z+1) swoou =0y | © EESE0L 66109 SULVL 687185 oVl VTS (1 3j0u soj0u) Jou ‘awiooul BUIO| 2 sy seiov's L660E's Lyvoze Bz voBEL'E suogessdo woy anueasy| L (@auanv) |(azuanvnn) [(aauanvnn) | (aauanvnn) | (@3uanvnn) | (@3tanvn) SYVINDILAVL MM 5202 JEW 1€ | 52021995 OF | 9¢0¢ 1995 0 | 52021005 0¢ | 920z aunr oc | 5202 W8S 0¢ [EMERTETN 030N ¥V3A 41VH Q30N3 ¥318VND Texep oreus Aiba 150 19a3x o Ul 27 9202 ¥3BW3LJTS 0F G3ANI HVIA 4TVH ONV HILHVND 3HL HOd SLINSIY TVIONVNIA G3LIANYNN INOTWANYLS 40 LNIWILYLS wodeueydsuesy W AIeie1008uedwod :[Iew-] ‘WY euLIRYdSURSYIEW MMM :SUSGIM ‘000Z 005220 "N duoydajal £50007-{eqUINY ‘(153/] HAYPUY ‘eIeMISO ‘PEOY UOISUDIXI (ESAQ £J09A INAPUEIS ‘4001 UIk} B3O PaIalsIBay $9£9900TdZ66 LHINOH 52T NID AL YINEVHY SNYSHEVIN
Page 4
MARKSANS PHARMA LIMITED STANDALONE UNAUDITED STATEMENT OF ASSETS AND LIABILITIES " _(zinmillion ) Particulars As at As at 30Sept2026 | 31 Mar 2026 (UNAUDITED) (AUDITED) ASSETS Non-current assets Property, plant and equipment 3,614.87 3,686.75 Right of use assets. 260.89 275.23 Other intangible assets 48.87 17.59 Financial assets Investments 3,730.78 267213 Other financial assets 12.07 11.46 Other non-current assets 197.26 175.54 Non Current tax assets (net) 8.25 10.81 Total non-current assets 7,872.99 6,849.51 Current assets Inventories 2,099.54 1,891.30 Financial assets Investments 623.69 - Trade receivables 5,228.83 6,234.62 Cash and cash equivalents 1,389.08 912.50 Bank balances other than above 3,192.69 3,565.15 Other financial assets 132.81 33.33 Other current assets 385.89 463.88 Total current assets 13,052.54 13,090.78 TOTAL ASSETS 20,925.53 19,940.29 EQUITY AND LIABILITIES EQUITY Equity share capital 453.16 45316 Other equity 17,265.60 16,069.94 Total equity 17,718.76 16,623.10 LIABILITIES Non-current liabilities Financial liabilities Lease liabilities 76.57 87.21 Provisions 26.42 56.91 Deferred tax liabilities (net) 182.36 170.57 Total non current liabilities 285.36 314.69 Current liabilities Financial liabilities Lease liabilities 34.00 34.08 Trade payables Total outstanding dues of micro and small enterprises 21.29 2012 Total outstanding dues of other than micro and small enterprises 173611 1,785.01 Other financial liabilities 172.43 25291 Other current liabilities 845.12 769.06 Provisions 3.37 3.18 Current tax liabilities (net) 109.10 23514 Total current liabilities. 2,921.42 3,102.50 Total liabilities 3,206.77 3,417.19 I TOTAL EQUITY AND LIABILITIES 20,925.53 19,940.29 e
Page 5
MARKSANS PHARMA LIMITED STANDALONE UNAUDITED CASH FLOW STATEMENT (Alt amounts in miltion of Indian Rupees, unless otherwise stated) Half Year ended Half Year ended Particulars 30 September 2026 30 September 2025 (UNAUDITED) (UNAUDITED) A Cash flow from operating activities Profit before tax 1,906.71 1,850.67 Adjustments to reconcile profit before tax to net cash provided by operating activities ~Depreciation and amortisation expenses. 178.26 166.44 ~Unrealised exchange differences on translation of assets and liabilities, net 198.36 (160.07) ~Loss on sale of property, plant and equipment, net 085 0.02 ~Gain on redemption of mutual fund fnvestments (1.86) (0.49) ~Finance costs 677 617 ~Employee Share based compensation expenses 31.78 0.70 ~Dividend income from a subsidiary (446.67) (386.16) “Interest income (130.81) (76.85) - (Gain) / oss arising on financial instruments measured at FVTPL, net (75.86) 76.39 ~Gain on lease termination (0.68) - ~Allowance for credit losses on trade receivables (including bad debts) 852 94.75 Operating profit before working capital changes 1,675.37 1,571.57 Changes in working capital Inventories (208.23) 39.89 Trade receivables 797.56 (646.98) Non-current/current financial and other assets 78.10 156.50 Non-current/current financtal and other liabilities/provisions/trade payables (16.27) (625.21) Cash generated from operations. 2,326.53 495.77 Income taxes paid (net) “74.37) (310.91) Net cash generated from operating activities (A) 1,852.16 184.86 8. Cash flow from investing activities: Payments to acquire property, plant and equipment and intangible assets. 137.71) (328.08) Proceeds from sale of property, plant and equipment - 2.62 Proceeds from deposits (net) 362.47 264.26 Purchase of mutual fund Investments (815.00) (340.00) Proceeds from sale of mutual fund investments 200.00 340.49 Payment for acquisition of subsidiaries (1,037.90) Dividend income from a subsidiary 446.67 386.16 Interest received 31.74 80.97 Net Cash (used In) / generated from investing activities (8) (949.73) 406.42 €. Cash flow from financing activities: Dividend paid {407.85) (362.53) Payment of principal partion of lease liabilities (including interest on lease tiabilities) (17.98) (14.09) Net Cash used in financing activities (C) (425.83) (376.62) Net increase in cash and cash equivalents (A+B+C) 476.60 214.66 Cash and cash equivalents at the beginning of the period 912.50 602.68 Effect of exchange differences on translation of foreign currency cash and cash equivalents (0.01) 0.03) Cash and cash equivalents at the end of the perod 1,389.09 817.31 Notes: 1 The above Cash Flow Statement is prepared under the “Indirect Method" as st out in Ind AS 7,' Statement of Cash Flows. 2 Amounts in bracket represent cash outflow.
Page 6
MARKSANS PHARMA LIMITED NOTES TO STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2026 1 The standalone unaudited financial results of the Company for the quarter and half year ended 30 September 2026 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 04 November 2026, The Statutory Auditors of the Campany have carried out a limited review of the above results in terms of Regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 (the Regulations), as amended and expressed an unmodified conclusion. 2 The standalone unaudited financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in terms of the Regulations. 3 The Company operates in one reportable business segment namely Pharmaceuticals’ as per Ind AS 108 on ‘Operating Segments. 4 Other income (net) includes the following net foreign exchange differences, including forward contracts: Description Quarter ended Half year ended Year Ended 30-Sep-26 30-Jun-26 30-Sep-25 30-Sep-26 30-Sep-25 31-Mar-26 Net gain 50.98 - 104.78 175.10 155.76 137.37 474.26 5 During the half year ended 30 September 2026, the Company has acquired 100% share capital of QliniQ B.V., a Company based in Netherlands, for a consideration of EUR 7.50 Million. QliniQ B.V. specializes in bringing innovative healthcare solutions to the Dutch market through the marketing and distribution of prescription medicines and medical devices. 6 During the quarter ended 30 September 2026, the Company has acquired 100% share capital ABCnow GmbH, a Germany- based pharmaceutical Company with frontend sales, marketing, and distribution capabilities across German healthcare market, for a cash consideration of EUR 1,10 Million. 7 During the half year ended 30 September 2026, the Company granted 300,000 stock options under the Marksans Employees Stock Option Scheme 2024 to eligible employees of the Company and its subsidiary companies. Each stock option is exercisable into ane equity share of the Company having a face value of Z1 each. 8 The above standalone unaudited financials results are available on the Company's website (www.marksanspharma.com) and stock exchanges websites, BSE (www.bseindia.com) and NSE (www.nseindia,com), where the sharesg#the Company are listed. Ging Director DIN: 00020983 Date : 04 November 2026 Place: Mumbai www.marksanspharma.com
Page 7
MSKA & Associates LLP o0 Flor 6, Rahesa Tianum (Formerly known as M S K A & Associates) "l{laeirtem g:(%:/ss :;rgrtn\:‘/:y,a feGeotanj:Sn © wa ) 3 Chartered Accountants e 0006, MDA o o Tel: +91 22 6974 0200 Independent Auditor’s Review Report on consolidated unaudited financial results of Marksans Pharma Limited for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Marksans Pharma Limited 1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Marksans Pharma Limited (hereinafter referred to as ‘the Holding Company’), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the ‘Group’) for the quarter ended 30 September 2026 and the year to-date results for the period from 01 April 2026 to 30 September 2026 (‘the Statement’) attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘the Regulations’). 2. This Statement, which is the responsibility of the Holding Company’s Management and approved by the Holding Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’ prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued thereunder (‘Ind AS 34’) and other recognised accounting principles generally accepted in india and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’ issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable. 4. This Statement includes the results of the Holding Company and the following entities: Sr. No Name of the Entity Relationship with the Holding Company 1 Marksans Pharma (UK) Limited Wholly owned subsidiary 2 Relonchem Limited Wholly owned subsidiary of Marksans Pharma (UK) Limited Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India Tel: +91 22 6974 0200 | LLPIN: ACT-3789 Ahmedabad | Bengaluru | Chandigarh | Chennai | Coimbatore | Goa | Gurugram | Hyderabad | Kochi | Kolkata | Pune www.mska.in
Page 8
MSKA & Associates LLP (Formerly known as M S K A & Associates) Chartered Accountants Sr. No | Name of the Entity Relationship with the Holding Company 3 Marksans Holdings Limited Wholly owned subsidiary of Marksans Pharma (UK) Limited 4 Bell, Sons and Co. (Druggists) Wholly owned subsidiary of Marksans Holdings Limited Limited 5 Marksans Pharma Inc. Wholly owned subsidiary 6 Time-Cap Laboratories Inc. Wholly owned subsidiary of Marksans Pharma Inc. 7 Marise Ann Inc. Wholly owned subsidiary of Marksans Pharma Inc. 8 Custom Coating Inc. Wholly owned subsidiary of Time-Cap Laboratories Inc. 9 Marksans Realty LLC Wholly owned subsidiary of Time-Cap Laboratories Inc. 10 Nova Pharmaceuticals Australasia Subsidiary (60% Holding) Pty Ltd 1 Nova Pharmaceuticals Limited Wholly owned subsidiary of Nova Pharmaceuticals Australasia Pty Ltd 12 Access Healthcare for Medical Wholly owned subsidiary Products L.L.C. 13 Marksans Pharma GmbH Wholly owned subsidiary 14 Marksans Pharma (Europe) Limited, | Wholly owned subsidiary Ireland 15 Marksans (Canada), Inc. Wholly owned subsidiary 16 QliniQ B.V. Wholly owned subsidiary, w.e.f. 01 April 2026 17 ABCnow Gmbh Wholly owned subsidiary, w.e.f. 01 July 2026 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India Tel: +91 22 6974 0200 | LLPIN: ACT-3789 Ahmedabad | Bengaluru | Chandigarh | Chennai | Coimbatore | Goa | Gurugram | Hyderabad | Kochi | Kolkata | Mumbai | Pune www.mska.in
Page 9
MSKA & Associates LLP (Formerly known as M S K A & Associates) Chartered Accountants 6. The Statement includes the interim financial information of eight subsidiaries which have not been reviewed by their auditors, whose interim financial information, before giving effect to the consolidation adjustments, reflects total assets of Rs. 3,142.39 million as at 30 September 2026 and total revenue of Rs. 1,421.68 million and Rs. 2,726.96 million, total net profit after tax of Rs. 27.50 million and Rs. 122.64 million and total comprehensive income of Rs. 27.50 million and Rs. 122.64 million for the quarter ended 30 September 2026 and for the period from 01 April 2026 to 30 September 2026, respectively, and cash flows (net) of Rs. 355.56 million for the period from 01 April 2026 to 30 September 2026, as considered in the Statement. These interim financial information have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group. Our conclusion is not modified in respect of the above matter with respect to our reliance on the financial information certified by the management. For MS K A & Associates LLP (Formerly known as M S K A & Associates) Chartered Accountants ICAl Firm Registration No.105047W/W101187 By~ Nitin Tiwari Partner Membership No.: 118894 UDIN:26 €934 1DPPT $338¢ | Place: Mumbai Date: 04 November 2026 Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India Tel: +91 22 6974 0200 | LLPIN: ACT-3789 Ahmedabad | Bengaluru | Chandigarh | Chennai | Coimbatore | Goa | Gurugram | Hyderabad | Kochi | Kolkata | Mumbai | Pune wwwmska.in
Page 10
Pas|enLUE US3G 10U aNEY “9Z0Z BUNT OF P3PUB JaLeND AU PUE G207 J2quRIdaS OF PUB GZ0Z IPGWIIDS OE POPUS J2K Jley puU Jsenb au) 10} S P S Twe SVE £ e e e paInIig zzs sv'e 659 ne we e oiseg .4e3 12 Jo 21eys Aunba sad sBuLEa| ZL orBLLEL finbs 20| 1L 91'Esy 9y s1esy ovesy sLesy 9L'esy 1ed Aiiny yoee 12 anien sdey) feydeD aieys Aunb3 dn ped| oL 502 86708 €245 861 vse v’z 1531341 BUOAU0D-UON 65°168°G. 6ETLST seLvv'e 6L'9ee"t 1588L') 89802} Auedwog 3y 0 s;0uMQ| ~:0) BIqEINQUNE SWOU] InSUBYRIAWOD (2I10] 688y vzer o6 8601 vee %9 Sis2133U) BUYIOIOY-WON 65TLLL 22900 ovzor 69658 06991 95°56¢ fuedwo au) 1o SI0UM0)| -0} aqEINqUIE BWOoU) BAISUYRIdWIOD I3I0 v91T [ esy X3 ovze £z sisessUl BuljoluoD-LoN 0061y 19595 61186 05286 P zLELyL Aueduwiog 8y jo S1eUAO| -0} 21qLINGLNE 1WoId BN Z1Z96s 26509 BV'L05°C 90958 VoL IWIELT (g+2) swodul aaisusyRIdWOD [e10L| 6 8'LoLL 96620 oLZLY 199t YZ0LL Z6°L0¢ 8Wwoou| sasUBYaIdWOD WG| 8 207152 ovIE0 96997 1¥'59¢ Y9291 Ze662 (15u) enseses vone|sue Aouauno UBR0 550 40 yoid 0} pelyisseloal 2 1M ey swol| (05°€) 450 (een 920 (eg0) (52°0) anoge uo xey 168k toz) 169 (001 e 343 SuE|d aUag PaUYSP JBU BU} JO SjUBWAINSEIWRY $50] 40 JJo1d 0} PayyIsEII21 3G 10U [[IM ey SWaY| 2w00u| enIsUBYBAWOD 14IO| Y9002 WELSTL ZE6L0E 60166 1065'L AT (e-9) XeL Jouy ayoid| L LEY0bL 16°625 T8 SELVE b'LLY 8L'66Y asuadx3 xey eol| 9 (z0se) (v2'82) (60CH) [EZED) (oz"2v) Lse xe| pasajeq (9)| e'oe - (010 - (010 - pouad sa|jsea Jo) Xe) Juauny ()| vo'66r'L 59vSS 19886 15858 vE8LS 979y xe1juaun) (€) :osuadx3 xeL| 555095 ZE660T VL 000 VEELE L 125902 £0SE6 L (r-¢) xeL eiopg oid| § 8L°62L T 6L°9/G'L1 SPbT YL 10°980°9 62°965'9 S1°89'L sasuadsg oL v 9v6159 16'1ETE YEVERE ZTSETL 1000271 VLT sesuadxe Jauo| © 28986 £1°008 sL698 91692 vo'8T Lize osuadxa vonestiowe pue uoneaita| 4 sT19T ogLL ogBEL . 5189 YO0L 9289 51500 SoU 3 YE60Z'Y 881202 60956 £0880°L eyl sLezz't asusdxe sieuaq ssodua| @ (L1vee't) (66'922'1) 6L (02'252) (25°951) €892 SPei-URPOIS pue| ) 55216010-Ul-/0M 'SPOO PRYSIULY JO SBUCIUBAL Ut SBUELD 88"y 88907 61047 1190'L 6pvec's opLiEL BPRI-UI00}S J0 sseyINd| 8 80265'6 vLPOZ'Y £9'125'% 0Tz 69'902'Z VEPLET pawnsuoo sieualew jo 1500| v sasuady| L LVECOE 199D 6LShE L 186LYL 002998 61'€856 (z+1) awoouy 01| € ee5e8 sreie bSSEY ZsIT a3 05181 (1 e10u Jojon) jou ‘awoour Jeo| 8E'605'6C 96°80v'eL 5960821 60%02'L 96'20v'8 69'10v'5 suonesado woy snusnay| | (a3nanv) | (@3uianvin) | (@aanvnn) | (@asianvnn | (@asianynn) | (aauanvnn) SHYINOLLYV .HM 920z ‘el 1€ [ 62023955 0¢ | 9202395 OF | £2023d9G O | 920 ounr 0 | 6202 3995 0¢ [CENERTEIN 30N ¥YIA IIVH Q30N3 ¥3LEVND Terep aaeys Ajnbs 3ad idsaxe uo Uy 2) 9207 ¥3AWI L3S 0F OIONI YYIA FTVH GNV ¥ILUVND JHL HO4 SLINS3M TYIONVNIA QILIANYNN GALYAIIOSNOD 40 LNIWILVLS woa-eueydsuesewDAie1oi00sKueduios (jlew-3 'wod BwBYASUTSHIEL MMM BHSAOM LLOZ LOOP-ZZ0 “ON X8 ‘000Z L0220 ON auoydajay £50005-12QUINI ‘1S9/A] HAUPUY 'EIRMIUSO ‘PEOY UOISUBIXA (BSO] EISIA UNGPUEID “JOOL YL | 199140 PeoIsIBay $9£990071dZ66LHINOLLYZT IO QILINIT VINSVHE SNYSYIVIU
Page 11
MARKSANS PHARMA LIMITED CONSOLIDATED UNAUDITED STATEMENT OF ASSETS AND LIABILITIES (% in million ) Particulars As at As at 30 Sept 2026 31 Mar 2026 (UNAUDITED) (AUDITED) ASSETS Non-current assets Property, plant and equipment 6,428.66 6,250.06 Right of use assets. 411261 3,008.70 Capital work-in-progress 50.90 147.82 Goodwill 1,026.29 452,56 Other intangible assets 1,076.06 729.74 Intangible assets under development 484.02 438.02 Financial assets Other financial assets 40.00 3872 Deferred tax assets (net) 49.33 129.65 Other non-current assets 197.26 175.54 Non current tax assets (net) 8.25 10.81 Total non-current assets 13,473.38 11,381.62 Current assets Inventories 9,956.82 9,722.81 Financial Assets Investments. 623.69 - Trade receivables 7,574.11 6,445.66 Cash and cash equivalents 7,419.98 6,341.37 Bank balances other than above 3,192.69 3,565.14 Other financial assets 158.12 49.26 Other current assets. 1,144.66 1,004.62 Current tax assets (net) 52.77 108.54 Total current assets 30,122.84 27,227.40 TOTAL ASSETS 43,596.22 38,600.02 EQUITY AND LIABILITIES EQUITY . Equity share capital 453.16 453.16 Other equity 32,870.32 29,778.40 Equity attributable to owners of the Company 33.323.48 30,231.56 Non-Controlling interests 349.47 295.24 Total equity 33,672.95 30,526.80 LIABILITIES Non-current liabilities Financial liabilities Lease liabilities 3,860.94 2,701.30 Provisions 29.88 59.15 Deferred tax liabilities (net) 29.15 50.87 Total non current liabilities 3,919.98 2,811.32 Current liabilities Financial ilabilities Borrowings 290.41 295.91 Lease liabilities 494.65 436.58 Trade payables Total outstanding dues of micro and small enterprises. 21.29 20.12 Total outstanding dues of other than micro and small enterprises 3,908.63 3,348.97 Other financial liabilities 379.96 301.30 Other current lial 3 614.32 449,01 Provisions 3.37 3.18 Current tax liabilities (net) 290.66 415.83 Total current liabilities 6,003.29 5,270.90 Total liabilities 9,923.27 8,082.22 [TOTAL EQUITY AND LIABILITIES 43,596.22 38,609.02
Page 12
MARKSANS PHARMA LIMITED CONSOLIDATED UNAUDITED CASH FLOW STATEMENT (All amounts in million of Indian Rupees, unless otherwise stated) Half Year ended Half Year ended Particulars 30 September 2026 30 September 2025 (UNAUDITED) (UNAUDITED) 'K Cash flow from operating activities Profit before tax 4,000.74 2,099.32 Adjustments to recancile profit before tax to net cash provided by operating activities “Depreciation and amortisation expenses 569.75 500.17 “Unrealised exchange differences on translation of assets and liabilties, net 198.3 1160.07) “Loss on sale of property, plant and equipment, net 085 [ “Gain on redemption of mutual fund Ivestments 1.86) (©49) “Finance costs 138.30 118.80 “Employee Share based compensation expenses 52.53 124 Interest income 218.66) 1124.66) (Gain) / oss arising on financial instruments measured at FVTPL, net (75.86) 739 “Gain on lease termination (0.68) - ~Allowance for credit losses on trade recefvables including bad debis) 196.86 122.08 ‘Operating profit before working capital changes 486033 2,632.30 Changes In working capital: Inventories (37.80) (©38.39) Trade recefvables (849.05) (343.95) Non-currentcurrent financial and other assets 162.59) (15.42) Non-current/current financial and other Uizbiities/pravisions/trade payables. 62 (188.02) Cash generated from operations . 4265.51 1,447.22 Income tax paid (net) 01.050.35) (€95.3) Net cash generated from operating activities (A) 3,215.16 751.86 8. Cash flow from investing activities: Payments to acquire property, plant and equipment an (460.94) 731.89) Procseds from sate of property, plant and equipment 262 Proceeds from deposits (net) 36246 25.23 Purchase of mutual fund Investments 815.00) (40.00) Proceeds from sale of mutual fund investments 200.00 049 Payment for acquisition of subsidiaries, net of cash acquired (Refer Note 5 and €) ©47.01) - Interest received 11959 1878 Net Cash used In fnvesting activities () (1,440.50) @847 C. Cash flow from financing activties: Dividend paid (407.85) (62.5%) {Repayment) / proceeds of short term borrowings (net) 7.4 290 Payment of principel portion of lease liabilities (including interest on lease liabiities) 27.20) (154.98) Interest cost paid 13.10) 1.6 Net Cash used In financing activities (C) (©95.64) 628.77) Net increase / (decrease) in cash and cash equivalents (A+B+C) 1,078.62 (141.68) Cash and cash equivalents at the beginning of the period 6.301.37 4.957.86 Effect of exchange differences on transiation of foreign currency cash and cash equivalents w01 ©.0% Cash and cash equivalents at the end of the perlod 7419.38 816,15 Wotes: 1 The above Cash Flow Statement is prepared under the “Indirect Method" 3s set out in Ind A5 7,"Statement of Cash Flows’. 2 Amounts in bracket represent cash outflow.
Page 13
MARKSANS PHARMA LIMITED NOTES TO CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2026 1 The consolidated unaudited financial results of the Company for the quarter and half year ended 30 September 2026 of Marksans Pharma Limited (the Company’ or 'the holding Company) and its subsidiarles (collectively referred as ‘the group) were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 04 November 2026. The Statutory Auditors of the Company have carried out a limited review of the above results in terms of Regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 (the Regulations), as amended and expressed an unmodified conclusion. 2 The consolidated unaudited financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in terms of the Regulations. 3 The Group has a single business segment 'Pharmaceuticals’ as per Ind AS 108 on ‘Operating Segments. 4 Other income (net) includes the following net foreign exchange differences, including forward contracts: Description Quarter ended Half year ended Year ended 30-5ep-26 30-Jun-26 30-Sep-25 30-Sep-26 30-5ep-25 31-Mar-26 Net gain 55.15 120.01 173.76 175.16 134.83] 500.95 5 During the half year ended 30 September 2026, the Company has acquired 100% share capital of QliniQ B.V., a Company based in Netherlands, for a consideration of EUR 7.50 Million. QUniQ B.V. specializes in bringing innovative healthcare solutions to the Dutch market through the marketing and distribution of prescription medicines and medical devices. QliniQ B.V. s a subsidiary of the Company w.e.f. 1 April 2026. As per Ind AS 103 on ‘Business Combinations’, purchase consideration has been allocated on a provisional basis, pending final determination of the fair value of the acquired assets and liabilities. 6 During the quarter ended 30 September 2026, the Company has acquired 100% share capital ABCnow GmbH, a Germany based pharmaceutical Company with frontend sales, marketing, and distribution capabilities across German healthcare market, for a cash consideration of EUR 1.10 Million. ABCnow GMBH is a subsidiary of the Company w.e.f. 1 July 2026. As per Ind AS 103 on ‘Business Combinations’, purchase consideration has been allocated on a provisional basis, pending final determination of the fair value of the acquired assets and liabilities. 7 During the half year ended 30 September 2026, the Company granted 300,000 stock options under the Marksans Employees Stock Option Scheme 2024 to eligible employees of the Company and its subsidiary companies. Each stock option is exercisable into one equity share of the Company having a face value of ¥1 each. 8 The above consolidated unaudited financials results are available on the Company's website {(www.marksanspharma.com) and stock exchanges websites, BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed. @naging Director DIN: 00020983 Date : 04 November 2026 - Place: Mumbai www.marksanspharma.com